Novartis takes a 15% stake in stem cell developer and an option to buy
Novartis is to invest $35m in stem cell therapy developer Gamida Cell in exchange for a 15% stake of the Israeli firm and an option to acquire the company.
Novartis is to invest $35m in stem cell therapy developer Gamida Cell in exchange for a 15% stake of the Israeli firm and an option to acquire the company.